2026-04-13T07:15:00Zhttps://recercat.cat/oai/request

oai:recercat.cat:2072/4784962025-04-03T11:24:07Zcom_2072_98col_2072_378192

00925njm 22002777a 4500 dc Henríquez-Hernández, Luis Alberto author Valenciano, Almudena author Foro, Palmira author Álvarez-Cubero, María Jesús author Cozar, José Manuel author Suárez-Novo, José Francisco author Castells-Esteve, Manel author Fernández-Gonzalo, Pablo author De-Paula-Carranza, Belén author Ferrer, Montse author Guedea, Ferrán author Sancho-Pardo, Gemma author Craven-Bartle, Jordi author Ortiz-Gordillo, María José author Cabrera-Roldán, Patricia author Herrera-Ramos, Estefanía author Rodríguez-Gallego, Carlos author Rodríguez-Melcón, Juan Ignacio author Lara, PedroC. author Universitat Autònoma de Barcelona author 2014 Background: Besides serum levels of PSA, there is a lack of prostate cancer specific biomarkers. It is need to develop new biological markers associated with the tumor behavior which would be valuable to better individualize treatment. The aim of this study was to elucidate the relationship between single nucleotide polymorphisms (SNPs) in genes involved in DNA repair and prostate cancer progression. Methods: A total of 494 prostate cancer patients from a Spanish multicenter study were genotyped for 10 SNPs in XRCC1, ERCC2, ERCC1, LIG4, ATM and TP53 genes. The SNP genotyping was made in a Biotrove OpenArray® NT Cycler. Clinical tumor stage, diagnostic PSA serum levels, and Gleason score at diagnosis were obtained for all participants. Genotypic and allelic frequencies were determined using the web-based environment SNPator. Results: SNPs rs11615 (ERCC1) and rs17503908 (ATM) appeared as risk factors for prostate cancer aggressiveness. Patients wild homozygous for these SNPs (AA and TT, respectively) were at higher risk for developing cT2b - cT4 (OR = 2.21 (confidence interval (CI) 95% 1.47 - 3.31), p < 0.001) and Gleason scores ≥ 7 (OR = 2.22 (CI 95% 1.38 - 3.57), p < 0.001), respectively. Moreover, those patients wild homozygous for both SNPs had the greatest risk of presenting D'Amico high-risk tumors (OR = 2.57 (CI 95% 1.28 - 5.16)). Conclusions: Genetic variants at DNA repair genes are associated with prostate cancer progression, and would be taken into account when assessing the malignancy of prostate cancer. ATM DNA repair ERCC1 OpenArray Prostate cancer Single nucleotide polymorphism Spanish cohort Single nucleotide polymorphisms in DNA repair genes as risk factors associated to prostate cancer progression